Diarrhea - Pipeline Insight, 2025
Description
DelveInsight’s, “Diarrhea - Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Diarrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Diarrhea: Overview
Diarrhea is having three or more loose or liquid stools (poos) in one day, or more frequently than normal. Diarrhea episodes are often caused by a stomach bug (gastroenteritis) and clear up on their own in a few days. However, there are many other causes of diarrhea. Most diarrhea is mild, but it can also be severe even needing admission to hospital. Diarrhea is the augmentation of water content in stools because of an imbalance in the normal functioning of physiologic processes of the small and large intestine responsible for the absorption of various ions, other substrates, and consequently water. Acute diarrhea is described as the acute onset of three or more loose or watery stools a day lasting for 14 days or less. However, chronic or persistent diarrhea is labeled when an episode lasts beyond 14 days. Infection commonly causes acute diarrhea. Noninfectious etiologies become more common as the duration of diarrhea becomes chronic. This distinction is important because treatment and management are based on the duration and specific etiology. Rehydration therapy is an important aspect of the management of any patient with diarrhea. Prevention of infectious diarrhea includes proper handwashing to prevent the spread of infection. The term ""acute gastroenteritis"" is synonymously used with ""acute diarrhea""; however, the former is a misnomer. The term gastroenteritis signifies both gastric and small intestinal involvement, whereas, practically gastric involvement is almost never seen in acute diarrhea even if it is the infective form of diarrhea. In developed regions, acute diarrhea is almost always a benign, self-resolving condition that subsides in a few days. The duration of illness and clinical presentation vary on the basis of the etiology of diarrhea and the host factors. For instance, rotavirus commonly presents with vomiting, dehydration, and more workdays lost than nonrotavirus diarrhea.
Typically, a patient with acute diarrhea will have a self-limited course and will not require labs or imaging. A stool culture is warranted in a patient with bloody diarrhea or severe illness to rule out bacterial causes. Bloody stools require additional testing for Shiga toxin and lactoferrin. A patient with recent antibiotic use or hospitalization will require testing for Clostridium difficile infection. Imaging is not ordered routinely in a patient with acute diarrhea. However, an abdominal CT may be required when a patient presents with significant peritoneal signs. In diarrhea, a stool pH of under 5.5 or the abundance of reducing substances signifies carbohydrate intolerance usually secondary to viral illnesses.
An important aspect of diarrhea management is replenishing fluid and electrolyte loss. Patients should be encouraged to drink diluted fruit juice. In more severe cases of diarrhea, IV fluid rehydration may become necessary. Eating foods that are lower in fiber may aid in making stool firmer. A bland 'BRAT' diet including bananas, toast, oatmeal, white rice, applesauce and soup/broth is well tolerated and may improve symptoms. Anti-diarrheal therapy with anti-secretory or anti-motility agents may be started to reduce the frequency of stools. However, they should be avoided in adults with bloody diarrhea or high fever because they can worsen severe intestinal infections. Water is a good way to replace fluids, but it doesn't contain the salts and electrolytes minerals such as sodium and potassium that are essential for our body to function. Empiric antibiotic therapy with an oral fluoroquinolone can be considered in patients with more severe symptoms. Probiotic supplementation has been shown to reduce the severity and duration of symptoms and should be encouraged in patients with acute diarrhea.
""Diarrhea - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diarrhea pipeline landscape is provided which includes the disease overview and Diarrhea treatment guidelines. The assessment part of the report embraces, in depth Diarrhea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diarrhea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Diarrhea report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diarrhea Emerging Drugs
Further product details are provided in the report……..
Diarrhea Therapeutic Assessment
This segment of the report provides insights about the different Diarrhea drugs segregated based on following parameters that define the scope of the report, such as:
Diarrhea Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Diarrhea therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diarrhea drugs.
Diarrhea Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Diarrhea: Overview
Diarrhea is having three or more loose or liquid stools (poos) in one day, or more frequently than normal. Diarrhea episodes are often caused by a stomach bug (gastroenteritis) and clear up on their own in a few days. However, there are many other causes of diarrhea. Most diarrhea is mild, but it can also be severe even needing admission to hospital. Diarrhea is the augmentation of water content in stools because of an imbalance in the normal functioning of physiologic processes of the small and large intestine responsible for the absorption of various ions, other substrates, and consequently water. Acute diarrhea is described as the acute onset of three or more loose or watery stools a day lasting for 14 days or less. However, chronic or persistent diarrhea is labeled when an episode lasts beyond 14 days. Infection commonly causes acute diarrhea. Noninfectious etiologies become more common as the duration of diarrhea becomes chronic. This distinction is important because treatment and management are based on the duration and specific etiology. Rehydration therapy is an important aspect of the management of any patient with diarrhea. Prevention of infectious diarrhea includes proper handwashing to prevent the spread of infection. The term ""acute gastroenteritis"" is synonymously used with ""acute diarrhea""; however, the former is a misnomer. The term gastroenteritis signifies both gastric and small intestinal involvement, whereas, practically gastric involvement is almost never seen in acute diarrhea even if it is the infective form of diarrhea. In developed regions, acute diarrhea is almost always a benign, self-resolving condition that subsides in a few days. The duration of illness and clinical presentation vary on the basis of the etiology of diarrhea and the host factors. For instance, rotavirus commonly presents with vomiting, dehydration, and more workdays lost than nonrotavirus diarrhea.
Typically, a patient with acute diarrhea will have a self-limited course and will not require labs or imaging. A stool culture is warranted in a patient with bloody diarrhea or severe illness to rule out bacterial causes. Bloody stools require additional testing for Shiga toxin and lactoferrin. A patient with recent antibiotic use or hospitalization will require testing for Clostridium difficile infection. Imaging is not ordered routinely in a patient with acute diarrhea. However, an abdominal CT may be required when a patient presents with significant peritoneal signs. In diarrhea, a stool pH of under 5.5 or the abundance of reducing substances signifies carbohydrate intolerance usually secondary to viral illnesses.
An important aspect of diarrhea management is replenishing fluid and electrolyte loss. Patients should be encouraged to drink diluted fruit juice. In more severe cases of diarrhea, IV fluid rehydration may become necessary. Eating foods that are lower in fiber may aid in making stool firmer. A bland 'BRAT' diet including bananas, toast, oatmeal, white rice, applesauce and soup/broth is well tolerated and may improve symptoms. Anti-diarrheal therapy with anti-secretory or anti-motility agents may be started to reduce the frequency of stools. However, they should be avoided in adults with bloody diarrhea or high fever because they can worsen severe intestinal infections. Water is a good way to replace fluids, but it doesn't contain the salts and electrolytes minerals such as sodium and potassium that are essential for our body to function. Empiric antibiotic therapy with an oral fluoroquinolone can be considered in patients with more severe symptoms. Probiotic supplementation has been shown to reduce the severity and duration of symptoms and should be encouraged in patients with acute diarrhea.
""Diarrhea - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diarrhea pipeline landscape is provided which includes the disease overview and Diarrhea treatment guidelines. The assessment part of the report embraces, in depth Diarrhea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diarrhea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Diarrhea R&D. The therapies under development are focused on novel approaches to treat/improve Diarrhea
This segment of the Diarrhea report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diarrhea Emerging Drugs
- VE303: Vedanta Biosciences, Inc.
- RHB-102: RedHill Biopharma Limited
- VR-AD-1005: Hunazine Biotech
- ShigETEC: Eveliqure Biotechnologies GmbH
Further product details are provided in the report……..
Diarrhea Therapeutic Assessment
This segment of the report provides insights about the different Diarrhea drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Diarrhea
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Diarrhea Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Diarrhea therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diarrhea drugs.
Diarrhea Report Insights
- Diarrhea Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Diarrhea drugs?
- How many Diarrhea drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diarrhea?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diarrhea therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Diarrhea and their status?
- What are the key designations that have been granted to the emerging drugs?
- RedHill Biopharma Limited
- Puma Biotechnology, Inc.
- Hunazine Biotech
- Vedanta Biosciences, Inc.
- Crinetics Pharmaceuticals Inc.
- MGB Biopharma Limited
- Daewoong pharmaceutical Co. LTD.
- Eveliqure Biotechnologies GmbH
- Inmunova S.A.
- GlaxoSmithKline
- RHB-102
- Neratinib
- VR-AD-1005
- VE303
- Paltusotine
- MGB-BP-3
- DWJ1230
- ShigETEC
- INM004
- altSonflex
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Diarrhea : Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Diarrhea – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- VE303: Vedanta Biosciences, Inc.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- VR-AD-1005: Hunazine Biotech
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- ShigETEC: Eveliqure Biotechnologies GmbH
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Diarrhea Key Companies
- Diarrhea Key Products
- Diarrhea - Unmet Needs
- Diarrhea - Market Drivers and Barriers
- Diarrhea - Future Perspectives and Conclusion
- Diarrhea Analyst Views
- Diarrhea Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
